Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00348595
First received: June 30, 2006
Last updated: May 21, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)